Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
aap Implantate AG is a medical technology company headquartered in Berlin, Germany, specializing in the development, manufacture, and marketing of innovative trauma products for orthopedics. Its primary focus is on traumatology solutions, including the proprietary LOQTEQ anatomical plating system designed for fracture treatment in areas such as the ankle joint, knee, elbow, wrist, and shoulder, alongside straight plates and cannulated screws. The company also advances an innovation pipeline featuring antibacterial silver coating technology and magnesium-based implants to address unmet needs in trauma care. As the parent of the aap Group, it includes 100% subsidiaries like aap Implants Inc. in the US, MCTeQ GmbH, and MAGIC Implants GmbH, all in Berlin, plus a stake in AEQUOS Endoprothetik GmbH. aap Implantate AG distributes products directly to hospitals, purchasing groups, and hospital networks in Germany, while leveraging a network of distributors across approximately 25 countries internationally, including hybrid strategies in the US. Founded in 1990, it plays a key role in the global orthopedics market by providing IP-protected implants that support bone healing and skeletal repair.
€1.50
€0.09 (-5.66%)
EOD Aug 14, 2026
The business is unprofitable at the operating level (-20.40% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 2.3%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -€2M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€12M
▲ +2.3% YoY
Net Income (TTM)
-€3M
▲ +28.8% YoY
Op. Margin
-20.40%
▲ +1.9pp YoY
ROIC
-19.06%
▼ -1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€2M
▼ -48.5% YoY
Op. Cash Flow (TTM)
-€2M
▼ -46.4% YoY
Net Debt
-€419K
Net Cash Position
Cash & Equiv.
€1M
3Y CAGR: +2.7%
Continue Research
aap Implantate (AAQ1.XETR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, aap Implantate scores 33/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
aap Implantate scores 33 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -20.4% operating margin and a -19.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AAQ1.XETR's valuation and scores 33/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.